PE20170926A1 - Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson - Google Patents
Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinsonInfo
- Publication number
- PE20170926A1 PE20170926A1 PE2017000864A PE2017000864A PE20170926A1 PE 20170926 A1 PE20170926 A1 PE 20170926A1 PE 2017000864 A PE2017000864 A PE 2017000864A PE 2017000864 A PE2017000864 A PE 2017000864A PE 20170926 A1 PE20170926 A1 PE 20170926A1
- Authority
- PE
- Peru
- Prior art keywords
- adhd
- parkinson
- disease
- treatment
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Se refiere al compuesto N-[4-(furan-2-il)-5-(tetrahidropiran-4-ilcarbonil)-tiazol-2-il]-2-metilpiridin-5-carboxamida [compuesto 504] de formula (I). Tambien se refiere a una composicion farmaceutica. Dicho compuesto es un antagonista del receptor A2A, siendo util en el tratamiento del trastorno por deficit de atencion con hiperactividad (TDAH) y la enfermedad de Parkinson.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201400704 | 2014-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20170926A1 true PE20170926A1 (es) | 2017-07-13 |
Family
ID=58731664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017000864A PE20170926A1 (es) | 2014-12-03 | 2015-12-01 | Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson |
Country Status (25)
Country | Link |
---|---|
US (2) | US20160158211A1 (es) |
EP (1) | EP3226863A1 (es) |
JP (1) | JP2017536400A (es) |
KR (1) | KR20170090430A (es) |
CN (1) | CN106999480A (es) |
AU (1) | AU2015357197A1 (es) |
BR (1) | BR112017011777A2 (es) |
CA (1) | CA2966582A1 (es) |
CL (1) | CL2017001407A1 (es) |
CO (1) | CO2017004785A2 (es) |
CR (1) | CR20170221A (es) |
DO (1) | DOP2017000121A (es) |
EA (1) | EA201790973A1 (es) |
EC (1) | ECSP17030050A (es) |
IL (1) | IL252355A0 (es) |
MA (1) | MA41090A (es) |
MX (1) | MX2017007027A (es) |
NI (1) | NI201700066A (es) |
PE (1) | PE20170926A1 (es) |
PH (1) | PH12017500923A1 (es) |
SG (1) | SG11201704370XA (es) |
SV (1) | SV2017005441A (es) |
TN (1) | TN2017000174A1 (es) |
TW (1) | TW201632186A (es) |
WO (1) | WO2016087429A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7490631B2 (ja) | 2018-07-05 | 2024-05-27 | インサイト・コーポレイション | A2a/a2b阻害剤としての縮合ピラジン誘導体 |
MX2021008094A (es) | 2019-01-11 | 2021-09-21 | Omeros Corp | Metodos y composiciones para el tratamiento del cancer. |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
CN114917350B (zh) * | 2022-06-21 | 2023-06-13 | 重庆医科大学附属第二医院 | Cftr增强剂在注意缺陷与多动障碍中的应用及产品 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1700856B1 (en) * | 2003-12-26 | 2015-11-11 | Kyowa Hakko Kirin Co., Ltd. | Thiazole derivative |
EA023267B1 (ru) * | 2008-07-23 | 2016-05-31 | Киова Хакко Кирин Ко., Лтд. | Способ для лечения и/или предотвращения мигрени |
TWI548411B (zh) * | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
UA110097C2 (uk) * | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
UA113383C2 (xx) * | 2009-09-02 | 2017-01-25 | Терапевтичний агент для лікування тривожних розладів |
-
2015
- 2015-11-30 MA MA041090A patent/MA41090A/fr unknown
- 2015-12-01 EP EP15802121.2A patent/EP3226863A1/en not_active Withdrawn
- 2015-12-01 KR KR1020177015211A patent/KR20170090430A/ko not_active Application Discontinuation
- 2015-12-01 SG SG11201704370XA patent/SG11201704370XA/en unknown
- 2015-12-01 CN CN201580064814.4A patent/CN106999480A/zh not_active Withdrawn
- 2015-12-01 JP JP2017529636A patent/JP2017536400A/ja not_active Withdrawn
- 2015-12-01 PE PE2017000864A patent/PE20170926A1/es not_active Application Discontinuation
- 2015-12-01 TW TW104140137A patent/TW201632186A/zh unknown
- 2015-12-01 US US14/955,148 patent/US20160158211A1/en not_active Abandoned
- 2015-12-01 CA CA2966582A patent/CA2966582A1/en not_active Withdrawn
- 2015-12-01 MX MX2017007027A patent/MX2017007027A/es unknown
- 2015-12-01 EA EA201790973A patent/EA201790973A1/ru unknown
- 2015-12-01 BR BR112017011777A patent/BR112017011777A2/pt not_active Application Discontinuation
- 2015-12-01 TN TN2017000174A patent/TN2017000174A1/en unknown
- 2015-12-01 WO PCT/EP2015/078181 patent/WO2016087429A1/en active Application Filing
- 2015-12-01 AU AU2015357197A patent/AU2015357197A1/en not_active Withdrawn
- 2015-12-01 CR CR20170221A patent/CR20170221A/es unknown
-
2017
- 2017-05-12 CO CONC2017/0004785A patent/CO2017004785A2/es unknown
- 2017-05-12 SV SV2017005441A patent/SV2017005441A/es unknown
- 2017-05-16 DO DO2017000121A patent/DOP2017000121A/es unknown
- 2017-05-16 EC ECIEPI201730050A patent/ECSP17030050A/es unknown
- 2017-05-17 IL IL252355A patent/IL252355A0/en unknown
- 2017-05-18 PH PH12017500923A patent/PH12017500923A1/en unknown
- 2017-06-01 NI NI201700066A patent/NI201700066A/es unknown
- 2017-06-02 CL CL2017001407A patent/CL2017001407A1/es unknown
- 2017-11-10 US US15/809,378 patent/US20180125835A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW201632186A (zh) | 2016-09-16 |
EP3226863A1 (en) | 2017-10-11 |
EA201790973A1 (ru) | 2017-10-31 |
KR20170090430A (ko) | 2017-08-07 |
MX2017007027A (es) | 2017-08-24 |
CA2966582A1 (en) | 2016-06-09 |
AU2015357197A1 (en) | 2017-05-25 |
TN2017000174A1 (en) | 2018-10-19 |
DOP2017000121A (es) | 2017-07-15 |
US20160158211A1 (en) | 2016-06-09 |
BR112017011777A2 (pt) | 2018-02-20 |
PH12017500923A1 (en) | 2017-11-20 |
CL2017001407A1 (es) | 2018-01-05 |
SV2017005441A (es) | 2017-08-25 |
SG11201704370XA (en) | 2017-06-29 |
JP2017536400A (ja) | 2017-12-07 |
MA41090A (fr) | 2017-10-10 |
CN106999480A (zh) | 2017-08-01 |
US20180125835A1 (en) | 2018-05-10 |
CO2017004785A2 (es) | 2017-08-31 |
ECSP17030050A (es) | 2017-08-31 |
IL252355A0 (en) | 2017-07-31 |
WO2016087429A1 (en) | 2016-06-09 |
NI201700066A (es) | 2018-01-04 |
CR20170221A (es) | 2017-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016002812A1 (es) | Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación. | |
NI201700011A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
UY36452A (es) | Novedosos compuestos moduladores de fxr (nr1h4) | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
CL2014002757A1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
CL2015002698A1 (es) | Nuevos compuestos y composiciones para la inhibicion de fasn | |
EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
ECSP16078782A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
PE20160609A1 (es) | Piperidil-etil-pirimidina sustituido como inhibidor de grelina o-acil transferasa | |
ECSP11011294A (es) | Compuestos de anillo fusionados y su uso | |
BR112016028749A2 (pt) | composto, forma cristalina, composição farmacêutica, e, método para o tratamento de uma doença. | |
PE20171243A1 (es) | Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados | |
BR112017004673A2 (pt) | formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida | |
CR20160460A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
PE20170926A1 (es) | Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson | |
AR128459A2 (es) | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación | |
CL2015003195A1 (es) | Derivados de purina como agonistas del receptor cb2. | |
CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FX | Voluntary withdrawal |